CSF-1R inhibitors, compositions, and methods of use

US8293769B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Simon Ng · Walnut Creek, US
• Keith B. Pfister · Emeryville, US
• Martin Sendzik · Belmont, US
• James Sutton · Princeton Junction, US
• Allan S. Wagman · Belmont, US
• Marion Wiesmann · Emeryville, US

Key dates

• Filing date: May 20, 2008
• Grant date: Oct 23, 2012
• Expiry date: Jan 14, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.